Nuvation Bio Inc (NUVB NYSE) stock market data APIs
$5.6984
0(0%)
as of July 7, 2026
Try our APIs with
free plan!
Nuvation Bio Inc Financial Data Overview
Price chart is built with
Anychart
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Prev. Close
5.6984
Open
5.7028
High
5.9025
Low
5.5012
52 wk Range
2.06-9.75
Market Cap
1 974 M
Shares Outstanding
347 M
Revenue
143 M
EPS
0.0382
Beta
1.527
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Nuvation Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nuvation Bio Inc data using free add-ons & libraries
Get Nuvation Bio Inc Fundamental Data
Nuvation Bio Inc Fundamental data includes:
- Net Revenue: 143 M
- EBITDA: -148 214 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-19
- EPS/Forecast: -0.0432
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nuvation Bio Inc News
New
Is Nuvation Bio’s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative?
In late June 2026, Nuvation Bio announced that partner Eisai's Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non-small cell lung cancer was validated by the U.K. MHRA...
Doctor-turned-dealmaker reveals his M&A playbook
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. From a headline-generating $14 billion deal with Pfizer for...
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?
Key Points According to a Form 4 filing, a Nuvation Bio executive reported selling 125,000 Class A shares for a total value of $753,000 on June 23, 2026. This transaction represented 79.32% of Markel...
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?
On June 23, 2026, Stacy Markel, Chief People Officer at Nuvation Bio Inc. (NYSE:NUVB), exercised 125,000 options for Class A Common Stock and sold the resulting shares for a transaction value of appro...
Get Nuvation Bio Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
